| Ongoing Investigation: Cytokinetics, Incorporated (CYTK) May Have Misled Shareholders - Levi & Korsinsky Investigates |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. |
accessnewswire.com |
2025-05-16 14:15:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK. |
accessnewswire.com |
2025-05-16 14:00:00 |
Czytaj oryginał (ang.) |
| ATTENTION Cytokinetics, Incorporated (CYTK) Investors: Possible Fraud - Contact Levi & Korsinsky Today |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. |
accessnewswire.com |
2025-05-15 14:30:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect |
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK. |
accessnewswire.com |
2025-05-15 14:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology |
Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 30th, 2025 from 8:00 AM to 6:00 PM Pacific Time. |
globenewswire.com |
2025-05-15 11:30:00 |
Czytaj oryginał (ang.) |
| ATTENTION CYTK Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. |
accessnewswire.com |
2025-05-14 14:15:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK. |
accessnewswire.com |
2025-05-14 14:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics: PDUFA Date Extension For Aficamten Is Not At All Earth Shattering |
Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted REMS. Positive phase 3 MAPLE-HCM study results show aficamten significantly outperformed metoprolol in treating symptomatic obstructive hypertrophic cardiomyopathy patients. The company is also targeting non-obstructive HCM patients with the ongoing phase 3 ACACIA-HCM study, with topline results expected in the first half of 2026. |
seekingalpha.com |
2025-05-13 20:06:52 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Investigates Possible Securities Fraud Violations by Cytokinetics, Incorporated (CYTK) |
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. |
accessnewswire.com |
2025-05-13 14:30:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK. |
accessnewswire.com |
2025-05-13 14:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics' heart disease drug meets main goal in late-stage study |
Cytokinetics said on Tuesday its experimental heart disease drug met the main goal in a late-stage study. |
reuters.com |
2025-05-13 11:45:48 |
Czytaj oryginał (ang.) |
| Cytokinetics Announces Positive Topline Results From MAPLE-HCM |
Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from MAPLE-HCM (Metoprolol vs A ficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a Phase 3 clinical trial comparing aficamten as monotherapy to the standard of care beta blocker metoprolol as monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). |
globenewswire.com |
2025-05-13 11:30:00 |
Czytaj oryginał (ang.) |
| Cytokinetics, Incorporated Being Investigated on Behalf of Cytokinetics, Incorporated Investors. Contact Levi & Korsinsky For Details |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. |
accessnewswire.com |
2025-05-12 14:15:00 |
Czytaj oryginał (ang.) |
| Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK. |
accessnewswire.com |
2025-05-12 14:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics, Incorporated Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- CYTK |
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. |
accessnewswire.com |
2025-05-11 15:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect |
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK. |
accessnewswire.com |
2025-05-11 14:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics, Incorporated Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - CYTK |
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. |
accessnewswire.com |
2025-05-09 14:15:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Stockholders to Connect |
NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK. |
accessnewswire.com |
2025-05-09 14:00:00 |
Czytaj oryginał (ang.) |
| Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm |
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CYTOKINETICS, INCORPORATED (CYTK), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Wha. |
businesswire.com |
2025-05-08 22:54:00 |
Czytaj oryginał (ang.) |
| Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress |
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025. |
globenewswire.com |
2025-05-08 20:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates |
Cytokinetics (CYTK) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.38 per share a year ago. |
zacks.com |
2025-02-27 20:15:30 |
Czytaj oryginał (ang.) |
| Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update |
Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and China |
globenewswire.com |
2025-02-27 18:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-20 13:05:37 |
Czytaj oryginał (ang.) |
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 14, 2025 it granted stock options to purchase an aggregate of 23,337 shares of common stock and 15,153 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 6 employees, whose employment commenced in February 2025, as a material inducement to their employment. |
globenewswire.com |
2025-02-19 18:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics to Announce Fourth Quarter Results on February 27, 2025 |
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future. |
globenewswire.com |
2025-02-13 18:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics Names Robert E. Landry to Board of Directors |
Appointment Deepens Financial and Operational Expertise of Board as Company Approaches Potential Commercialization |
globenewswire.com |
2025-02-11 09:30:00 |
Czytaj oryginał (ang.) |
| Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:40 PM Eastern Time. |
globenewswire.com |
2025-02-05 18:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate of 64,587 shares of common stock, 41,939 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 6,066 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 13 employees, whose employment commenced in January 2025, as a material inducement to their employment. |
globenewswire.com |
2025-02-04 18:00:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm |
NEW YORK , Jan. 30, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Cytokinetics, Inc. (NASDAQ: CYTK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. |
prnewswire.com |
2025-01-30 14:22:00 |
Czytaj oryginał (ang.) |
| Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program |
Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach |
globenewswire.com |
2025-01-30 09:30:00 |
Czytaj oryginał (ang.) |
| CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study |
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients. |
zacks.com |
2025-01-23 14:21:09 |
Czytaj oryginał (ang.) |
| Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst |
Stifel initiated coverage on Cytokinetics Incorporated CYTK, noting the company's catalyst rich one to two years. |
benzinga.com |
2025-01-22 17:43:50 |
Czytaj oryginał (ang.) |
| Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction |
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥60%. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of with symptomatic HFpEF patients with hypercontractility and ventricular hypertrophy. |
globenewswire.com |
2025-01-21 09:30:00 |
Czytaj oryginał (ang.) |
| Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 |
PDUFA Target Action Date for Aficamten Set for September 26, 2025; Commercial Launch Preparations Underway for First Potential Approval |
globenewswire.com |
2025-01-13 09:30:00 |
Czytaj oryginał (ang.) |
| Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. |
globenewswire.com |
2025-01-06 18:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of 52,188 shares of common stock, 33,885 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 3,189 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 9 employees, whose employment commenced in December 2024, as a material inducement to their employment. |
globenewswire.com |
2025-01-03 18:00:00 |
Czytaj oryginał (ang.) |
| Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution |
Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy (HCM). Strategic licensing deals with Sanofi and Bayer secure resources and focus US commercialization. Clinical trials aim to expand aficamten's utility, including first-line and pediatric indications. |
seekingalpha.com |
2024-12-31 10:30:00 |
Czytaj oryginał (ang.) |
| Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy |
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP). |
globenewswire.com |
2024-12-23 09:30:00 |
Czytaj oryginał (ang.) |
| Why Cytokinetics Stock Was a Nearly 5% Winner Today |
California-based biotech Cytokinetcs (CYTK 4.56%) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in a key market abroad was the catalyst for the increase, which well exceeded the slightly over 1% gain of the S&P 500 index. |
fool.com |
2024-12-20 19:25:00 |
Czytaj oryginał (ang.) |
| Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China |
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM. |
globenewswire.com |
2024-12-20 02:00:00 |
Czytaj oryginał (ang.) |